The burden of drug resistance tuberculosis in Ghana; results of the First National Survey.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
14
03
2021
accepted:
21
05
2021
entrez:
10
6
2021
pubmed:
11
6
2021
medline:
10
11
2021
Statut:
epublish
Résumé
Resistance to Tuberculosis drugs has become a major threat to the control of tuberculosis (TB) globally. We conducted the first nation-wide drug resistance survey to investigate the level and pattern of resistance to first-line TB drugs among newly and previously treated sputum smear-positive TB cases. We also evaluated associations between potential risk factors and TB drug resistance. Using the World Health Organization (WHO) guidelines on conducting national TB surveys, we selected study participants from 33 health facilities from across the country, grouped into 29 clusters, and included them into the survey. Between April 2016 and June 2017, a total of 927 patients (859 new and 68 previously treated) were enrolled in the survey. Mycobacterium tuberculosis complex (MTBC) isolates were successfully cultured from 598 (65.5%) patient samples and underwent DST, 550 from newly diagnosed and 48 from previously treated patients. The proportion of patients who showed resistance to any of the TB drugs tested was 25.2% (95% CI; 21.8-28.9). The most frequent resistance was to Streptomycin (STR) (12.3%), followed by Isoniazid (INH) (10.4%), with Rifampicin (RIF), showing the least resistance of 2.4%. Resistance to Isoniazid and Rifampicin (multi-drug resistance) was found in 19 (3.2%; 95% CI: 1.9-4.9) isolates. Prevalence of multidrug resistance was 7 (1.3%; 95% CI: 0.5-2.6) among newly diagnosed and 12 (25.0%; 95% CI: 13.6-39.6) among previously treated patients. At both univariate and multivariate analysis, MDR-TB was positively associated with previous history of TB treatment (OR = 5.09, 95% CI: 1.75-14.75, p = 0.003); (OR = 5.41, 95% CI: 1.69-17.30, p = 0.004). The higher levels of MDR-TB and overall resistance to any TB drug among previously treated patients raises concerns about adherence to treatment. This calls for strengthening existing TB programme measures to ensure a system for adequately testing and monitoring TB drug resistance.
Identifiants
pubmed: 34111159
doi: 10.1371/journal.pone.0252819
pii: PONE-D-21-08420
pmc: PMC8191906
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0252819Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Bull World Health Organ. 2002;80(6):489-95; discussion 495-500
pubmed: 12132008
J Clin Microbiol. 2011 Apr;49(4):1202-5
pubmed: 21270230
Thorax. 2006 Feb;61(2):158-63
pubmed: 16254056
Infect Drug Resist. 2018 Feb 22;11:239-246
pubmed: 29503573
PLoS One. 2011;6(7):e21906
pubmed: 21779354
Ghana Med J. 2010 Jun;44(2):42-6
pubmed: 21327002
J Natl Med Assoc. 2018 Feb;110(1):88-91
pubmed: 29510850
Microb Drug Resist. 2009 Sep;15(3):217-21
pubmed: 19728781
PLoS Med. 2009 Sep;6(9):e1000146
pubmed: 19753109
Eur J Microbiol Immunol (Bp). 2019 Feb 06;9(1):23-28
pubmed: 30967972
Tubercle. 1989 Dec;70(4):249-55
pubmed: 2516670
Emerg Infect Dis. 2013 Mar;19(3):478-80
pubmed: 23621911
MMWR Morb Mortal Wkly Rep. 2006 Mar 24;55(11):301-5
pubmed: 16557213
Soc Sci Med. 2005 Aug;61(4):847-59
pubmed: 15896895
PLoS One. 2013 Aug 01;8(8):e70763
pubmed: 23936467
BMC Infect Dis. 2018 May 31;18(1):249
pubmed: 29855354
PLoS One. 2017 Sep 25;12(9):e0185105
pubmed: 28945771
Int J Tuberc Lung Dis. 2010 Aug;14(8):967-72
pubmed: 20626940
West Afr J Med. 2007 Apr-Jun;26(2):131-3
pubmed: 17939315
Int J Tuberc Lung Dis. 2006 Jun;10(6):649-55
pubmed: 16776452
Int J Tuberc Lung Dis. 2015 Aug;19(8):954-959
pubmed: 26162362
Eur Respir J. 2013 Jul;42(1):252-71
pubmed: 23180585
Eur J Microbiol Immunol (Bp). 2018 Aug 16;8(3):91-94
pubmed: 30345089
Emerg Infect Dis. 2006 Jul;12(7):1171-2
pubmed: 16848046
Tuberculosis (Edinb). 2016 Jul;99:147-154
pubmed: 27450017
Ann Intern Med. 2008 Jul 15;149(2):123-34
pubmed: 18626051
Lancet. 2005 Apr 2-8;365(9466):1206-9
pubmed: 15811438
West Afr J Med. 2001 Apr-Jun;20(2):92-7
pubmed: 11768026